Inflammatory response and haematological disorders in cardiac surgery: toward a more physiological cardiopulmonary bypass;Réponse inflammatoire et perturbations hématologiques en chirurgie cardiaque : vers une circulation extracorporelle plus physiologique

Annales Francaises d'Anesthesie et de Reanimation

Volumn 25, Issue 5, 2006, Pages 510-520

  Baufreton, C ^a   Corbeau, J J ^a   Pinaud, F ^a  

^a ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

Biocompatibility; Cardiac surgery; Cardiopulmonary bypass; Haematological disorders; Inflammatory response

Indexed keywords

HEPARIN; PROTAMINE; THROMBOPLASTIN;

BIOCOMPATIBILITY; BLOOD CLOTTING; CARDIOPULMONARY BYPASS; CELL ACTIVATION; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; EXTRACORPOREAL CIRCULATION; EXTRACORPOREAL OXYGENATION; HEART SURGERY; HEMATOLOGIC DISEASE; HEMOSTASIS; HUMAN; INFLAMMATION; LEUKOCYTE ACTIVATION; MONOCYTE; OFF PUMP SURGERY; ORGAN PERFUSION; PATHOPHYSIOLOGY; POSTOPERATIVE PERIOD; SHORT SURVEY; SPLANCHNIC BLOOD FLOW; THROMBOCYTE ACTIVATION;

ANESTHETICS; ANTICOAGULANTS; BIOCOMPATIBLE MATERIALS; BLOOD COAGULATION DISORDERS; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; COMPLEMENT ACTIVATION; CORONARY ARTERY BYPASS, OFF-PUMP; CYTOKINES; ENDOTOXINS; EQUIPMENT CONTAMINATION; EQUIPMENT DESIGN; GENETIC PREDISPOSITION TO DISEASE; HEPARIN; HUMANS; INFLAMMATION; INTRAOPERATIVE COMPLICATIONS; MYOCARDIAL REPERFUSION INJURY; POSTOPERATIVE COMPLICATIONS; PROTAMINES; SPLANCHNIC CIRCULATION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 33646269014     PISSN: 07507658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annfar.2005.12.002     Document Type: Short Survey

References (100)

1. Lehot J.J., Lefevre M., Phan T., Bastien O., Diab C., and Jegaden O. Que faut-il attendre de la chirurgie coronaire sans circulation extracorporelle ?. Ann. Fr. Anesth. Réanim. 23 (2004) 1063-1072
2. Menasche P. The systemic factor: the comparative roles of cardiopulmonary bypass and off-pump surgery in the genesis of patient injury during and following cardiac surgery. Ann. Thorac. Surg. 72 (2001) S2260-S2265 (discussion S2265-6, S2267-70)
3. Biglioli P., Cannata A., Alamanni F., Naliato M., Porqueddu M., Zanobini M., et al. Biological effects of off-pump vs on-pump coronary artery surgery: focus on inflammation, hemostasis and oxidative stress. Eur. J. Cardiothorac. Surg. 24 (2003) 260-269
4. Cartier R., Brann S., Dagenais F., Martineau R., and Couturier A. Systematic off-pump coronary artery revascularization in multivessel disease: experience of three hundred cases. J. Thorac. Cardiovasc. Surg. 119 (2000) 221-229
5. Edmunds Jr. L.H. Why cardiopulmonary bypass makes patients sick: strategies to control the blood-synthetic surface interface. Adv. Card. Surg. 6 (1995) 131-167
6. Boyle Jr. E.M., Verrier E.D., and Spiess B.D. Endothelial cell injury in cardiovascular surgery: the procoagulant response. Ann. Thorac. Surg. 62 (1996) 1549-1557
7. Boyle Jr. E.M., Pohlman T.H., Johnson M.C., and Verrier E.D. Endothelial cell injury in cardiovascular surgery: the systemic inflammatory response. Ann. Thorac. Surg. 63 (1997) 277-284
8. Baufreton C., Moczar M., Intrator L., Jansen P.G., te Velthuis H., Le Besnerais P., et al. Inflammatory response to cardiopulmonary bypass using two different types of heparin-coated extracorporeal circuits. Perfusion 13 (1998) 419-427
9. Baufreton C., Intrator L., Jansen P.G., te Velthuis H., Le Besnerais P., Vonk A., et al. Inflammatory response to cardiopulmonary bypass using roller or centrifugal pumps. Ann. Thorac. Surg. 67 (1999) 972-977
10. te Velthuis H., Jansen P.G., Oudemans-van Straaten H.M., Sturk A., Eijsman L., and Wildevuur C.R. Myocardial performance in elderly patients after cardiopulmonary bypass is suppressed by tumor necrosis factor. J. Thorac. Cardiovasc. Surg. 110 (1995) 1663-1669
11. Hennein H.A., Ebba H., Rodriguez J.L., Merrick S.H., Keith F.M., Bronstein M.H., et al. Relationship of the pro-inflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. J. Thorac. Cardiovasc. Surg. 108 (1994) 626-635
12. Wan S., LeClerc J.L., and Vincent J.L. Cytokine responses to cardiopulmonary bypass: lessons learned from cardiac transplantation. Ann. Thorac. Surg. 63 (1997) 269-276
13. te Velthuis H., Baufreton C., Jansen P.G., Thijs C.M., Hack C.E., Sturk A., et al. Heparin coating of extracorporeal circuits inhibits contact activation during cardiac operations. J. Thorac. Cardiovasc. Surg. 114 (1997) 117-122
14. Courtney J.M., Zhao X., and Qian H. Biomaterials in cardiopulmonary bypass. Perfusion 14 (1999) 263-267
15. Baufreton C., and de Brux J.L. Les traitements de surfaces en circulation extracorporelle. ITBM-RBM 21 (1999) 20-25
16. Bannan S., Danby A., Cowan D., Ashraf S., and Martin P.G. Low heparinization with heparin-bonded bypass circuits: is it a safe strategy?. Ann. Thorac. Surg. 63 (1997) 663-668
17. Baufreton C., Jansen P.G., Le Besnerais P., te Velthuis H., Thijs C.M., Wildevuur C.R., et al. Heparin coating with aprotinin reduces blood activation during coronary artery operations. Ann. Thorac. Surg. 63 (1997) 50-56
18. Lappegard K.T., Fung M., Bergseth G., Riesenfeld J., Lambris J.D., Videm V., et al. Effect of complement inhibition and heparin coating on artificial surface-induced leukocyte and platelet activation. Ann. Thorac. Surg. 77 (2004) 932-941
19. Wildevuur C.R., Jansen P.G., Bezemer P.D., Kuik D.J., Eijsman L., Bruins P., et al. Clinical evaluation of Duraflo II heparin treated extracorporeal circulation circuits (2nd version). The European working group on heparin coated extracorporeal circulation circuits. Eur. J. Cardiothorac. Surg. 11 (1997) 616-623 (discussion 24-5)
20. Ranucci M., Mazzucco A., Pessotto R., Grillone G., Casati V., Porreca L., et al. Heparin-coated circuits for high-risk patients: a multicenter, prospective, randomized trial. Ann. Thorac. Surg. 67 (1999) 994-1000
21. Jansen P.G., Baufreton C., Le Besnerais P., Loisance D.Y., and Wildevuur C.R. Heparin-coated circuits and aprotinin prime for coronary artery bypass grafting. Ann. Thorac. Surg. 61 (1996) 1363-1366
22. Bruins P., te Velthuis H., Yazdanbakhsh A.P., Jansen P.G., van Hardevelt F.W., de Beaumont E.M., et al. Activation of the complement system during and after cardiopulmonary bypass surgery: post-surgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation 96 (1997) 3542-3548
23. Ovrum E., Am Holen E., Tangen G., and Ringdal M.A. Heparinized cardiopulmonary bypass and full heparin dose marginally improve clinical performance. Ann. Thorac. Surg. 62 (1996) 1128-1133
24. Baufreton C., Le Besnerais P., Jansen P., Mazzucotelli J.P., Wildevuur C.R., and Loisance D.Y. Clinical outcome after coronary surgery with heparin-coated extracorporeal circuits for cardiopulmonary bypass. Perfusion 11 (1996) 437-443
25. Lazar H.L., Bao Y., Rivers S., Treanor P.R., and Shemin R.J. Decreased incidence of arterial thrombosis using heparin-bonded intra-aortic balloons. Ann. Thorac. Surg. 67 (1999) 446-449
26. Aldea G.S., Doursounian M., O'Gara P., Treanor P., Shapira O.M., Lazar H.L., et al. Heparin-bonded circuits with a reduced anticoagulation protocol in primary CABG: a prospective, randomized study. Ann. Thorac. Surg. 62 (1996) 410-417 (discussion 417-8)
27. Wendel H.P., and Ziemer G. Coating-techniques to improve the hemocompatibility of artificial devices used for extracorporeal circulation. Eur. J. Cardiothorac. Surg. 16 (1999) 342-350
28. Albes J.M., Stohr I.M., Kaluza M., Siegemund A., Schmidt D., Vollandt R., et al. Physiological coagulation can be maintained in extracorporeal circulation by means of shed blood separation and coating. J. Thorac. Cardiovasc. Surg. 126 (2003) 1504-1512
29. De Somer F., Francois K., van Oeveren W., Poelaert J., De Wolf D., Ebels T., et al. Phosphorylcholine coating of extracorporeal circuits provides natural protection against blood activation by the material surface. Eur. J. Cardiothorac. Surg. 18 (2000) 602-606
30. Ranucci M., Isgro G., Soro G., Canziani A., Menicanti L., and Frigiola A. Reduced systemic heparin dose with phosphorylcholine coated closed circuit in coronary operations. Int. J. Artif. Organs 27 (2004) 311-319
31. von Segesser L.K., Tonz M., Leskosek B., and Turina M. Evaluation of phospholipidic surface coatings ex vivo. Int. J. Artif. Organs 17 (1994) 294-299
32. Daniel S. Material and circuit related bio-incompatibility of cardiopulmonary bypass in cardiovascular surgery. In: Baykut D., and Krian A. (Eds). Current perspective of the extracorporeal circulation (2000), Steinkopff-Springer, Darmstadt 37-46
33. Hansbro S.D., Sharpe D.A., Catchpole R., Welsh K.R., Munsch C.M., McGoldrick J.P., et al. Haemolysis during cardiopulmonary bypass: an in vivo comparison of standard roller pumps, non-occlusive roller pumps and centrifugal pumps. Perfusion 14 (1999) 3-10
34. Ashraf S., Butler J., Tian Y., Cowan D., Lintin S., Saunders N.R., et al. Inflammatory mediators in adults undergoing cardiopulmonary bypass: comparison of centrifugal and roller pumps. Ann. Thorac. Surg. 65 (1998) 480-484
35. Welsby I.J., Podgoreanu M.V., Phillips-Bute B., Mathew J.P., Smith P.K., Newman M.F., et al. Genetic factors contribute to bleeding after cardiac surgery. J. Thromb. Haemost. 3 (2005) 1206-1212
36. Donahue B.S., Gailani D., Higgins M.S., Drinkwater D.C., and George Jr. A.L. Factor V Leiden protects against blood loss and transfusion after cardiac surgery. Circulation 107 (2003) 1003-1008
37. Gaudino M., Andreotti F., Zamparelli R., Di Castelnuovo A., Nasso G., Burzotta F., et al. The -174G/C interleukin-6 polymorphism influences postoperative interleukin-6 levels and postoperative atrial fibrillation. Is atrial fibrillation an inflammatory complication?. Circulation 108 Suppl 1 (2003) II195-II199
38. Brull D.J., Montgomery H.E., Sanders J., Dhamrait S., Luong L., Rumley A., et al. Interleukin-6 gene -174g>c and -572g>c promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1458-1463
39. Schroeder S., Borger N., Wrigge H., Welz A., Putensen C., Hoeft A., et al. A tumor necrosis factor gene polymorphism influences the inflammatory response after cardiac operation. Ann. Thorac. Surg. 75 (2003) 534-537
40. Ryan T., Balding J., McGovern E.M., Hinchion J., Livingstone W., Chughtai Z., et al. Lactic acidosis after cardiac surgery is associated with polymorphisms in tumor necrosis factor and interleukin 10 genes. Ann. Thorac. Surg. 73 (2002) 1905-1909 [discussion 10-1]
41. Drabe N., Zund G., Grunenfelder J., Sprenger M., Hoerstrup S.P., Bestmann L., et al. Genetic predisposition in patients undergoing cardiopulmonary bypass surgery is associated with an increase of inflammatory cytokines. Eur. J. Cardiothorac. Surg. 20 (2001) 609-613
42. Zhang S., Wang S., and Yao S. Evidence for development of capillary leak syndrome associated with cardiopulmonary bypass in pediatric patients with the homozygous C4A null phenotype. Anesthesiology 100 (2004) 1387-1393
43. Deng M.C., Dasch B., Erren M., Mollhoff T., and Scheld H.H. Impact of left ventricular dysfunction on cytokines, hemodynamics, and outcome in bypass grafting. Ann. Thorac. Surg. 62 (1996) 184-190
44. Matata B.M., and Galinanes M. Cardiopulmonary bypass exacerbates oxidative stress but does not increase pro-inflammatory cytokine release in patients with diabetes compared with patients without diabetes: regulatory effects of exogenous nitric oxide. J. Thorac. Cardiovasc. Surg. 120 (2000) 1-11
45. Remadi J.P., Rakotoarivello Z., Marticho P., Trojette F., Benamar A., Poulain H., et al. Aortic valve replacement with the minimal extracorporeal circulation (Jostra MECC system) vs standard cardiopulmonary bypass: a randomized prospective trial. J. Thorac. Cardiovasc. Surg. 128 (2004) 436-441
46. Schonberger J.P., Everts P.A., and Hoffmann J.J. Systemic blood activation with open and closed venous reservoirs. Ann. Thorac. Surg. 59 (1995) 1549-1555
47. Brown Mahoney C., and Donnelly J.E. Impact of closed vs open venous reservoirs on patient outcomes in isolated coronary artery bypass graft surgery. Perfusion 15 (2000) 467-472
48. Englberger L., Immer F.F., Eckstein F.S., Berdat P.A., Haeberli A., and Carrel T.P. Off-pump coronary artery bypass operation does not increase procoagulant and fibrinolytic activity: preliminary results. Ann. Thorac. Surg. 77 (2004) 1560-1566
49. Boisclair M.D., Lane D.A., Philippou H., Esnouf M.P., Sheikh S., Hunt B., et al. Mechanisms of thrombin generation during surgery and cardiopulmonary bypass. Blood 82 (1993) 3350-3357
50. Tabuchi N., de Haan J., Boonstra P.W., and van Oeveren W. Activation of fibrinolysis in the pericardial cavity during cardiopulmonary bypass. J. Thorac. Cardiovasc. Surg. 106 (1993) 828-833
51. Mariani M.A., Gu Y.J., Boonstra P.W., Grandjean J.G., van Oeveren W., and Ebels T. Procoagulant activity after off-pump coronary operation: is the current anticoagulation adequate?. Ann. Thorac. Surg. 67 (1999) 1370-1375
52. Gu Y.J., Mariani M.A., Boonstra P.W., Grandjean J.G., and van Oeveren W. Complement activation in coronary artery bypass grafting patients without cardiopulmonary bypass: the role of tissue injury by surgical incision. Chest 116 (1999) 892-898
53. de Haan J., Boonstra P.W., Monnink S.H., Ebels T., and van Oeveren W. Retransfusion of suctioned blood during cardiopulmonary bypass impairs hemostasis. Ann. Thorac. Surg. 59 (1995) 901-907
54. Kuitunen A.H., Heikkila L.J., and Salmenpera M.T. Cardiopulmonary bypass with heparin-coated circuits and reduced systemic anticoagulation. Ann. Thorac. Surg. 63 (1997) 438-444
55. Aldea G.S., O'Gara P., Shapira O.M., Treanor P., Osman A., Patalis E., et al. Effect of anticoagulation protocol on outcome in patients undergoing CABG with heparin-bounded cardiopulmonary bypass circuits. Ann. Thorac. Surg. 65 (1998) 425-433
56. Reents W., Babin-Ebell J., Misoph M.R., Schwarzkopf A., and Elert O. Influence of different autotransfusion devices on the quality of salvaged blood. Ann. Thorac. Surg. 68 (1999) 58-62
57. Anderson R.E., Hansson L.O., Liska J., Settergren G., and Vaage J. The effect of cardiotomy suction on the brain injury marker S100beta after cardiopulmonary bypass. Ann. Thorac. Surg. 69 (2000) 847-850
58. Kincaid E.H., Jones T.J., Stump D.A., Brown W.R., Moody D.M., Deal D.D., et al. Processing scavenged blood with a cell saver reduces cerebral lipid microembolization. Ann. Thorac. Surg. 70 (2000) 1296-1300
59. Shuhaibar M.N., Hargrove M., Millat M.H., O'Donnell A., and Aherne T. How much heparin do we really need to go on pump? A rethink of current practices. Eur. J. Cardiothorac. Surg. 26 (2004) 947-950
60. Baufreton C., de Brux J.L., Binuani P., Corbeau J.J., Subayi J.B., Daniel J.C., et al. A combined approach for improving cardiopulmonary bypass in coronary artery surgery: a pilot study. Perfusion 17 (2002) 407-413
61. Ranucci M., Cazzaniga A., Soro G., Isgro G., Frigiola A., and Menicanti L. The antithrombin III-saving effect of reduced systemic heparinization and heparin-coated circuits. J. Cardiothorac. Vasc. Anesth. 16 (2002) 316-320
62. Paparella D., Yau T.M., and Young E. Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update. Eur. J. Cardiothorac. Surg. 21 (2002) 232-244
63. Eikemo H., Sellevold O.F., and Videm V. Markers for endothelial activation during open heart surgery. Ann. Thorac. Surg. 77 (2004) 214-219
64. Videm V. Heparin in clinical doses "primes" granulocytes to subsequent activation as measured by myeloperoxidase release. Scand. J. Immunol. 43 (1996) 385-390
65. Khuri S.F., Valeri C.R., Loscalzo J., Weinstein M.J., Birjiniuk V., Healey N.A., et al. Heparin causes platelet dysfunction and induces fibrinolysis before cardiopulmonary bypass. Ann. Thorac. Surg. 60 (1995) 1008-1014
66. Baufreton C., Moreau X., Corbeau J.J., Pavie P., and De Brux J.L. Déroulement de la CEC standard et avec les nouveaux dispositifs consommables. In: Janvier G., and Lehot J.J. (Eds). Circulation extracorporelle : principes et pratique. Seconde ed (2004), Rueil-Malmaison: Arnette 113-145
67. Nakajima T., Kawazoe K., Ishibashi K., Kubota Y., Sasaki T., Izumoto H., et al. Reduction of heparin dose is not beneficial to platelet function. Ann. Thorac. Surg. 70 (2000) 186-190
68. Berliner S., Fishelson Z., Wasserman L., Pinkhas J., and Aronson M. Synergism between zymosan-activated serum and heparin in the induction of polymorphonuclear leukocyte aggregation. Biomed. Pharmacother. 42 (1988) 69-72
69. Okajima K., and Uchiba M. The anti-inflammatory properties of antithrombin III: new therapeutic implications. Semin. Thromb. Hemost. 24 (1998) 27-32
70. Habazettl H., Martinek V., Vollmar B., and Conzen P. Enhancement of the leukocyte-endothelial cell interaction in collecting venules of skeletal muscle by protamine. J. Thorac. Cardiovasc. Surg. 113 (1997) 784-791
71. Pevni D., Frolkis I., Iaina A., Wollman Y., Chernichovski T., Shapira I., et al. Protamine-induced cardiotoxicity is prevented by anti-TNF-alpha antibodies and heparin. Anesthesiology 95 (2001) 1389-1395
72. Shigeta O., Kojima H., Hiramatsu Y., Jikuya T., Terada Y., Atsumi N., et al. Low-dose protamine based on heparin-protamine titration method reduces platelet dysfunction after cardiopulmonary bypass. J. Thorac. Cardiovasc. Surg. 118 (1999) 354-360
73. Shandelya S.M., Kuppusamy P., Weisfeldt M.L., and Zweier J.L. Evaluation of the role of polymorphonuclear leukocytes on contractile function in myocardial reperfusion injury. Evidence for plasma-mediated leukocyte activation. Circulation 87 (1993) 536-546
74. Allen B.S., and Ilbawi M.N. Hypoxia, reoxygenation and the role of systemic leukodepletion in pediatric heart surgery. Perfusion 16 Suppl (2001) 19-29
75. Ihnken K., Winkler A., Schlensak C., Sarai K., Neidhart G., Unkelbach U., et al. Normoxic cardiopulmonary bypass reduces oxidative myocardial damage and nitric oxide during cardiac operations in the adult. J. Thorac. Cardiovasc. Surg. 116 (1998) 327-334
76. Suzuki T., Fukuda T., Ito T., Inoue Y., Cho Y., and Kashima I. Continuous pulmonary perfusion during cardiopulmonary bypass prevents lung injury in infants. Ann. Thorac. Surg. 69 (2000) 602-606
77. Nader N.D., Li C.M., Khadra W.Z., Reedy R., and Panos A.L. Anesthetic myocardial protection with sevoflurane. J. Cardiothorac. Vasc. Anesth. 18 (2004) 269-274
78. De Hert S.G., Van der Linden P.J., Cromheecke S., Meeus R., Nelis A., Van Reeth V., et al. Cardioprotective properties of sevoflurane in patients undergoing coronary surgery with cardiopulmonary bypass are related to the modalities of its administration. Anesthesiology 101 (2004) 299-310
79. De Hert S.G., Van der Linden P.J., Cromheecke S., Meeus R., ten Broecke P.W., De Blier I.G., et al. Choice of primary anaesthetic regimen can influence intensive care unit length of stay after coronary surgery with cardiopulmonary bypass. Anesthesiology 101 (2004) 9-20
80. Asimakopoulos G. The inflammatory response to CPB: the role of leukocyte filtration. Perfusion 17 Suppl (2002) 7-10
81. Gott J.P. Leukodepletion and aprotinin improve clinical outcome after extracorporeal circulation. Perfusion 16 Suppl (2001) 5-9
82. Treacher D.F., Sabbato M., Brown K.A., and Gant V. The effects of leucodepletion in patients who develop the systemic inflammatory response syndrome following cardiopulmonary bypass. Perfusion 16 Suppl (2001) 67-73
83. Journois D., and Bourdarias B. Hémofiltration en chirurgie cardiaque. In: Janvier G., and Lehot J.J. (Eds). Circulation extracorporelle: principes et pratique. Seconde ed (2004), Rueil-Malmaison: Arnette 377-385
84. Chew M.S. Does modified ultrafiltration reduce the systemic inflammatory response to cardiac surgery with cardiopulmonary bypass?. Perfusion 19 Suppl 1 (2004) S57-S60
85. Picone A.L., Lutz C.J., Finck C., Carney D., Gatto L.A., Paskanik A., et al. Multiple sequential insults cause post-pump syndrome. Ann. Thorac. Surg. 67 (1999) 978-985
86. Ohri S.K., Becket J., Brannan J., Keogh B.E., and Taylor K.M. Effects of cardiopulmonary bypass on gut blood flow, oxygen utilization, and intramucosal pH. Ann. Thorac. Surg. 57 (1994) 1193-1199
87. Jansen N.J., van Oeveren W., Gu Y.J., van Vliet M.H., Eijsman L., and Wildevuur C.R. Endotoxin release and tumor necrosis factor formation during cardiopulmonary bypass. Ann. Thorac. Surg. 54 (1992) 744-747 [discussion 7-8]
88. Ohri S.K., Bjarnason I., Pathi V., Somasundaram S., Bowles C.T., Keogh B.E., et al. Cardiopulmonary bypass impairs small intestinal transport and increases gut permeability. Ann. Thorac. Surg. 55 (1993) 1080-1086
89. Oudemans-van Straaten H.M., Jansen P.G., Hoek F.J., van Deventer S.J., Sturk A., Stoutenbeek C.P., et al. Intestinal permeability, circulating endotoxin, and postoperative systemic responses in cardiac surgery patients. J. Cardiothorac. Vasc. Anesth. 10 (1996) 187-194
90. Watarida S., Mori A., Onoe M., Tabata R., Shiraishi S., Sugita T., et al. A clinical study on the effects of pulsatile cardiopulmonary bypass on the blood endotoxin levels. J. Thorac. Cardiovasc. Surg. 108 (1994) 620-625
91. Jansen P.G., Te Velthuis H., Oudemans-Van Straaten H.M., Bulder E.R., Van Deventer S.J., Sturk A., et al. Perfusion-related factors of endotoxin release during cardiopulmonary bypass. Eur. J. Cardiothorac. Surg. 8 (1994) 125-129
92. Wright G., Ping J.S., Campbell C.S., and Tobias M.A. Computation of haemodynamic power and input impedance in the ascending aorta of patients undergoing open-heart surgery. Cardiovasc. Res. 22 (1988) 179-184
93. Morariu A.M., Gu Y.J., Huet R.C., Siemons W.A., Rakhorst G., and Oeveren W.V. Red blood cell aggregation during cardiopulmonary bypass: a pathogenic cofactor in endothelial cell activation?. Eur. J. Cardiothorac. Surg. 26 (2004) 939-946
94. Fisher A.B., Chien S., Barakat A.I., and Nerem R.M. Endothelial cellular response to altered shear stress. Am. J. Physiol. Lung Cell. Mol. Physiol. 281 (2001) L529-L533
95. James S.A., Peters J., Maresca L., Kalush S.L., and Trigueros E.A. The roller pump does produce pulsatile flow. J. Extra. Corpor. Technol. 19 (1987) 376-383
96. Fromes Y., Gaillard D., Ponzio O., Chauffert M., Gerhardt M.F., Deleuze P., et al. Reduction of the inflammatory response following coronary bypass grafting with total minimal extracorporeal circulation. Eur. J. Cardiothorac. Surg. 22 (2002) 527-533
97. Wiesenack C., Liebold A., Philipp A., Ritzka M., Koppenberg J., Birnbaum D.E., et al. Four years' experience with a miniaturized extracorporeal circulation system and its influence on clinical outcome. Artif. Organs 28 (2004) 1082-1088
98. Kiyama H., Imazeki T., Katayama Y., Murai N., Mukouyama M., and Yamauti N. Vacuum-assisted venous drainage in single-access minimally invasive cardiac surgery. J. Artif. Organs 6 (2003) 20-24
99. Jansen P.G., te Velthuis H., Bulder E.R., Paulus R., Scheltinga M.R., Eijsman L., et al. Reduction in prime volume attenuates the hyperdynamic response after cardiopulmonary bypass. Ann. Thorac. Surg. 60 (1995) 544-549 (discussion 9-50)
100. Eising G.P., Pfauder M., Niemeyer M., Tassani P., Schad H., Bauernschmitt R., et al. Retrograde autologous priming: is it useful in elective on-pump coronary artery bypass surgery?. Ann. Thorac. Surg. 75 (2003) 23-27